PEDIATRICS Vol. 99 No. 3 March 1997, pp. 354-357 (doi:10.1542/peds.99.3.354)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clarick, R. H.
Right arrow Articles by Chadwick, E. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clarick, R. H.
Right arrow Articles by Chadwick, E. G.
Related Collections
Right arrow Infectious Disease & Immunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PEDIATRICS Vol. 99 No. 3 March 1997, pp. 354-357

Megestrol Acetate Treatment of Growth Failure in Children Infected With Human Immunodeficiency Virus

Received Jan 26, 1996; accepted Apr 11, l996..

Robert H. Clarick, Willem A. Hanekom, Ram Yogev, and Ellen Gould Chadwick

From the Department of Pediatrics, Northwestern University, Children's Memorial Medical Center, Chicago, Illinois.

Objective.  To evaluate the effect of megestrol acetate on weight gain and linear growth in human immunodeficiency virus-infected children with growth failure.

Methods.  All human immunodeficiency virus-infected children with growth failure treated with megestrol acetate at our institution were evaluated retrospectively. Weight, height, and weight:height ratio were documented from 6 months before initiation of megestrol acetate until 6 months after treatment was discontinued. Measurements were corrected for age and sex by conversion to z-scores. Incremental growth was determined before, during, and after treatment. The potential effects of CD4+ T-lymphocyte count and percentage, antiretroviral therapy, and intercurrent illnesses on growth were evaluated.

Results.  Nineteen patients were treated with a total of 27 courses of megestrol acetate. The median duration of therapy was 7 months (range, 3 to 11 months), and the median megestrol acetate dose was 7.91 mg/kg/day (range, 4.06 to 8.56 mg/kg/day). From 6 months and 3 months before treatment to the onset of therapy, median changes in weight z-scores were -.27 and -.15, respectively. During megestrol acetate treatment, median changes in weight z-scores were +.29 after 1 month of therapy, +.40 after 3 months, and +.57 after 6 months. After megestrol acetate therapy was discontinued, poor weight gain and weight loss resumed. Median 6-month growth velocities for weight were less than the 10th percentile before megestrol acetate, greater than the 97th percentile during treatment, and less than the 3rd percentile after treatment was discontinued. Megestrol acetate therapy was not associated with changes in linear growth. Antiretroviral therapy, CD4+ T-lymphocyte count or percentage, or intercurrent illnesses were not associated with statistically significant differences in response to megestrol acetate therapy.

Conclusions.  Megestrol acetate treatment of growth failure in pediatric human immunodeficiency virus disease is associated with weight gain, without affecting linear growth.

Key words: human immunodeficiency virus, growth failure, megestrol acetate, nutrition.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 PediatricsHome page
T. L. Miller, B. E. Mawn, E. J. Orav, D. Wilk, G. A. Weinberg, J. Nicchitta, L. Furuta, R. Cutroni, K. McIntosh, S. K. Burchett, et al.
The Effect of Protease Inhibitor Therapy on Growth and Body Composition in Human Immunodeficiency Virus Type 1-Infected Children
Pediatrics, May 1, 2001; 107(5): 77e - 77.
[Abstract] [Full Text]

Home page
 PediatricsHome page
Antiretroviral Therapy and Medical Management of Pediatric HIV Infection
Pediatrics, October 1, 1998; 102(4): 1005 - 1062.
[Full Text]

Home page
 Topics in Early Childhood Special EducationHome page
K. Landry and T. Smith
Neurocognitive Effects of HIV Infection on Young Children: Implications for Assessment
Topics in Early Childhood Special Education, January 1, 1998; 18(3): 160 - 169.
[Abstract] [PDF]